What it is
Oxytocin is a nine-amino-acid peptide hormone synthesized in the hypothalamus and released into the bloodstream by the posterior pituitary. It has one long-settled pharmaceutical role: as Pitocin or Syntocinon, an injectable drug used to induce or strengthen labor and to control bleeding after childbirth. That use is well established and is not what this page, or the research-vendor market, is about.
Separately, over the last two decades, researchers have studied oxytocin delivered intranasally for its effects on trust, bonding, empathy, and social behavior, the source of its popular "love hormone" reputation. That is the research this page covers, and it is a considerably smaller and less settled body of evidence than the reputation suggests.
What the human research actually found
A systematic review by MacDonald and colleagues, published in Psychoneuroendocrinology in 2011, examined 38 randomized controlled trials of intranasal oxytocin conducted between 1990 and 2010, covering 1,529 participants.[1] Its main finding was about safety, not benefit: oxytocin produced no reliably detectable subjective changes and no consistent side effects distinguishable from placebo at the 18 to 40 IU doses used in research settings. Participants in these trials generally could not tell whether they had received oxytocin or a placebo.
Where researchers looked for a specific clinical benefit, the results were mixed at best. A randomized, double-blind trial by Guastella and colleagues, published in the same journal in 2009, gave 24 IU of oxytocin or placebo alongside exposure therapy to 25 people with social anxiety disorder.[2] Oxytocin improved participants' in-session self-ratings of their appearance and speech performance as treatment progressed, but that effect did not carry over into better overall outcomes from the therapy itself.
Why the reputation runs ahead of the evidence
Neuroendocrinologists Gareth Leng and Mike Ludwig addressed this gap directly in a 2016 review in Biological Psychiatry titled, without much subtlety, "Intranasal Oxytocin: Myths and Delusions."[3] Their argument is technical as much as it is skeptical: intranasally administered oxytocin is a large, charged peptide that crosses the blood-brain barrier poorly, and the pharmacokinetic case for it reaching the brain regions responsible for the effects attributed to it is weaker than most popular coverage assumes.
None of this means oxytocin does nothing, or that every study is flawed. It means the compound picked up a cultural story faster than it earned one, and that a single-dose nasal spray reaching a receptor system deep in the brain is a much harder proposition than "sniff this and feel more connected" suggests.
No vendor is currently listing this
Oxytocin isn't available from any vendor we currently track. It was last seen at $21.00 per mg on Penguin Peptides, 2 July 2026, listed as a 2 mg vial for $42.00. That figure is included here for reference. It's what the compound was actually selling for the last time we confirmed a listing, not a price you can act on today. If a vendor relists it, this page will reflect the live price the next time our data updates.
References
- [1] MacDonald E et al. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology. 2011;36(8):1114-1126. PubMed ↗
- [2] Guastella AJ et al. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology. 2009;34(6):917-923. PubMed ↗
- [3] Leng G, Ludwig M. Intranasal Oxytocin: Myths and Delusions. Biol Psychiatry. 2016;79(3):243-250. PubMed ↗